Large established B16 tumors in mice are eradicated by ZVex® (DC-targeting lentiviral vector) and G100 (TLR4 agonist) combination immunotherapy through increasing tumor-infiltrating effector T cells and antigen spreading

Tina A. Albershardt, Jardín Leleux, Andrea J. Parsons, Peter Berglund, and Jan ter Meulen

Immune Design, Seattle, WA and South San Francisco, CA

**INTRODUCTION**

Effective immunotherapy requires the presence of effector T cells (pervading the tumor. ZVex® (administered intradermally as subcutaneously) is a lentiviral vector platform that targets dendritic cells in vivo to express tumor-associated antigens (TAA) genes of interest and activate TAA-specific CD T cells. G100® (administered intratumorally) contains formulated glucosynaprosynap lipoprotein (synthetic TLR4 agonist) and induces T cell-homing chemokines, CXC10 and CXC11. We report here that G100® modulates the tumor microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/anti-TAA microenvironment (TME) and improves infiltration of ZVex®-induced TAA-specific CD T cells to the TME, thereby eradicating established B16 tumors, previously achieved only with a complex vaccincation/ant